Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
Tesla's Terafab: AI Chip Factory Eyes Taiwan's Semiconductor Talent 
Want to cut your energy bills? Here’s how five experts are doing it 
NiSource Signs Long-Term Energy Deals with Alphabet and Amazon to Power Indiana Data Centers 
Japan to Subsidize Sony's Image Sensor Plant in Kumamoto with $380 Million 
TSMC Posts Record Q1 Profit Fueled by AI Chip Demand 
Samsung Races to Deliver Next-Gen HBM4E Memory Samples to Nvidia 
Uber Bets Big on Autonomous Vehicles with $10 Billion Commitment 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
KKR's $820M Investment Fuels Samsung SDS AI Expansion, Sending Group Shares Soaring 
Hermès Q1 2026 Sales Miss Expectations Amid Iran War and China Slowdown 
Federal Judge Dismisses DOJ Lawsuit Attempting to Block Hawaii's Climate Case Against Oil Giants 
Daikin Industries Stock Surges 14% After Elliott Investment Management Discloses Major Stake 
Goldman Sachs FICC Revenue Falls 10% Amid Iran War Market Volatility 
Pentagon Taps Auto Giants to Supercharge U.S. Weapons Production 
Federal Agencies Secretly Test Anthropic's AI Despite Trump Administration Ban 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
WALTHAM, Mass., May 31, 2017 -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that company management will participate in the following investor conferences:
- Jefferies 2017 Global Healthcare Conference
Tuesday, June 6, 2017 at 9:30 a.m. ET
Location: New York, NY
- Goldman Sachs Leveraged Finance Conference
Tuesday, June 20, 2017 at 11:20 a.m. PT (2:20 p.m. ET)
Location: Palos Verdes, CA
To access the live webcasts, please visit the Investors section of the company’s website at www.amagpharma.com. A replay of each event will be archived on the site for 30 days.
About AMAG
AMAG is a biopharmaceutical company focused on developing and delivering important therapeutics, conducting clinical research in areas of unmet need and creating education and support programs for the patients and families we serve. Our currently marketed products support the health of patients in the areas of maternal and women’s health, anemia management and cancer supportive care. Through CBR®, we also help families to preserve newborn stem cells, which are used today in transplant medicine for certain cancers and blood, immune and metabolic disorders, and have the potential to play a valuable role in the ongoing development of regenerative medicine. For additional company information, please visit www.amagpharma.com.
AMAG Pharmaceuticals® is a registered trademark of AMAG Pharmaceuticals, Inc. and CBR® is a registered trademark of CBR Systems, Inc.
AMAG Pharmaceuticals Contact: Christi Waarich Associate Director, Investor Relations 617-498-7638
